228 related articles for article (PubMed ID: 38329524)
1. Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches.
Ebrahimpour M; Hosseinzadeh H; Abedi F; Nodeh MM; Allahyari A; Sahebkar A; Arasteh O
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4601-4614. PubMed ID: 38329524
[TBL] [Abstract][Full Text] [Related]
2. Management of Advanced Small Bowel Cancer.
Puccini A; Battaglin F; Lenz HJ
Curr Treat Options Oncol; 2018 Nov; 19(12):69. PubMed ID: 30397729
[TBL] [Abstract][Full Text] [Related]
3. Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice.
Mazlom H; Teuwen LA; Peeters M
Curr Opin Oncol; 2021 Jul; 33(4):368-371. PubMed ID: 33882527
[TBL] [Abstract][Full Text] [Related]
4. Progress in the Treatment of Small Intestine Cancer.
Symons R; Daly D; Gandy R; Goldstein D; Aghmesheh M
Curr Treat Options Oncol; 2023 Apr; 24(4):241-261. PubMed ID: 36826686
[TBL] [Abstract][Full Text] [Related]
5. Management of Small Bowel Neuroendocrine Tumors.
Scott AT; Howe JR
Surg Oncol Clin N Am; 2020 Apr; 29(2):223-241. PubMed ID: 32151357
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab in small bowel adenocarcinoma: a new friend?
Santini D; Fratto ME; Spoto C; Russo A; Galluzzo S; Zoccoli A; Vincenzi B; Tonini G
Br J Cancer; 2010 Oct; 103(8):1305; author reply 1306. PubMed ID: 20842127
[No Abstract] [Full Text] [Related]
7. Update on medical treatment of small intestinal neuroendocrine tumors.
Pusceddu S; Femia D; Lo Russo G; Ortolani S; Milione M; Maccauro M; Vernieri C; Prinzi N; Concas L; Leuzzi L; De Braud F; Buzzoni R
Expert Rev Anticancer Ther; 2016 Sep; 16(9):969-76. PubMed ID: 27353232
[TBL] [Abstract][Full Text] [Related]
8. Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994-2010: a population-based study.
Bojesen RD; Andersson M; Riis LB; Nielsen OH; Jess T
J Gastroenterol; 2016 Sep; 51(9):891-9. PubMed ID: 26847562
[TBL] [Abstract][Full Text] [Related]
9. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.
Sacdalan DB; Mendoza MJ; Vergara JP; Catedral LI; Ting FI; Leones LM; Berba CM; Sacdalan DL
Med Oncol; 2020 Nov; 37(11):106. PubMed ID: 33135102
[TBL] [Abstract][Full Text] [Related]
10. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
11. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
12. The evolving management of small bowel adenocarcinoma.
de Bree E; Rovers KP; Stamatiou D; Souglakos J; Michelakis D; de Hingh IH
Acta Oncol; 2018 Jun; 57(6):712-722. PubMed ID: 29381126
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study.
Bojesen RD; Riis LB; Høgdall E; Nielsen OH; Jess T
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1900-1907.e2. PubMed ID: 28694132
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
15. [Small bowel tumors: experience at the Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"].
Sánchez-Ramón A; Cerino-Palomino V; Medina-Franco H
Rev Gastroenterol Mex; 2012; 77(4):181-5. PubMed ID: 23177666
[TBL] [Abstract][Full Text] [Related]
16. [Progression of diagnosis and treatment in primary malignant small bowel tumor].
Zhao Z; Guan X; Chen Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):117-120. PubMed ID: 28105627
[TBL] [Abstract][Full Text] [Related]
17. Immunological evaluation of patients with adenocarcinoma of the large bowel on immunotherapy.
Wilkins SA; Olkowski ZL
Am J Proctol; 1977 Jun; 28(3):27-34. PubMed ID: 869020
[No Abstract] [Full Text] [Related]
18. Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.
Taghipour Zahir S; Heidarymeybodi Z; AleSaeidi S
Int J Surg Oncol; 2019; 2019():2912361. PubMed ID: 31186956
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
Oktay E; Yalcin GD; Ekmekci S; Kahraman DS; Yalcin A; Degirmenci M; Dirican A; Altin Z; Ozdemir O; Surmeli Z; Diniz G; Ayhan S; Bulut G; Erdogan A; Uslu R
J BUON; 2019; 24(2):779-790. PubMed ID: 31128036
[TBL] [Abstract][Full Text] [Related]
20. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
